The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis
Open accessAbstract
Importance: High blood pressure (BP) is the most important risk factor for death and cardiovascular disease (CVD) worldwide. The optimal cutoff for treatment of high BP is debated. Objective: To assess the association between BP lowering treatment and death and CVD at different BP levels. Data Sources: Previous systematic reviews were identified from PubMed, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effect. Reference lists of these reviews were searched for randomized clinical trials. Randomized clinical trials published after November 1, 2015, were also searched for in PubMed and the Cochrane Central Register for Controlled Trials during February 2017. Study Selection: Randomized clinical trials with at least 1000 patient-years of follow-up, comparing BP-lowering drugs vs placebo or different BP goals were included. Data Extraction and Synthesis: Data were extracted from original publications. Risk of bias was assessed using the Cochrane Collaborations assessment tool. Relative risks (RRs) were pooled in random-effects meta-analyses with Knapp-Hartung modification. Results are reported according to PRISMA guidelines. Main Outcomes and Measures: Prespecified outcomes of interest were all-cause mortality, cardiovascular mortality, major cardiovascular events, coronary heart disease (CHD), stroke, heart failure, and end-stage renal disease. Results: Seventy-four unique trials, representing 306 273 unique participants (39.9% women and 60.1% men; mean age, 63.6 years) and 1.2 million person-years, were included in the meta-analyses. In primary prevention, the association of BP-lowering treatment with major cardiovascular events was dependent on baseline systolic BP (SBP). In trials with baseline SBP 160 mm Hg or above, treatment was associated with reduced risk for death (RR, 0.93; 95% CI, 0.87-1.00) and a substantial reduction of major cardiovascular events (RR, 0.78; 95% CI, 0.70-0.87). If baseline SBP ranged from 140 to 159 mm Hg, the association of treatment with mortality was similar (RR, 0.87; 95% CI, 0.75-1.00), but the association with major cardiovascular events was less pronounced (RR, 0.88; 95% CI, 0.80-0.96). In trials with baseline SBP below 140 mm Hg, treatment was not associated with mortality (RR, 0.98; 95% CI, 0.90-1.06) and major cardiovascular events (RR, 0.97; 95% CI, 0.90-1.04). In trials including people with previous CHD and mean baseline SBP of 138 mm Hg, treatment was associated with reduced risk for major cardiovascular events (RR, 0.90; 95% CI, 0.84-0.97), but was not associated with survival (RR, 0.98; 95% CI, 0.89-1.07). Conclusions and Relevance: Primary preventive BP lowering is associated with reduced risk for death and CVD if baseline SBP is 140 mm Hg or higher. At lower BP levels, treatment is not associated with any benefit in primary prevention but might offer additional protection in patients with CHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationWilliams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
Epidemiology of cardiovascular disease in China: current features and implications
Zhao, D., Liu, J., Wang, M., Zhang, X., & Zhou, M. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0119-4 · Cited by 1,388
Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Ramakrishnan, R., Pinho-Gomes, A.-C., Woodward, M., Adler, A., Agodoa, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00590-0 · Cited by 1,074
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 464
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Ding, J., Davis-Plourde, K. L., Sedaghat, S., Tully, P. J., Wang, W., Phillips, C., Pase, M. P., Himali, J. J., Gwen Windham, B., Griswold, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30393-x · Cited by 312
Diagnosis and treatment of arterial hypertension [Guidelines]
Chazova, I. E., & Zhernakova, Y. V. (2019) · Systemic Hypertension · doi:10.26442/2075082x.2019.1.190179 · Cited by 274
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Long-term effects of weight-reducing diets in people with hypertension
Semlitsch, T., Jeitler, K., Berghold, A., Horvath, K., Posch, N., Poggenburg, S., & Siebenhofer, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008274.pub3 · Cited by 118
de Boer, I. H., Bakris, G., & Cannon, C. P. (2018) · JAMA · doi:10.1001/jama.2018.0642 · Cited by 54
Tsujimoto, T., & Kajio, H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11408 · Cited by 38
Zhou, H., Wang, X., Yang, Y., Chen, Z., Zhang, L., Zheng, C., Shao, L., Tian, Y., Cao, X., Hu, Z., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45439 · Cited by 30
Poulter, N. R., Castillo, R., Charchar, F. J., Schlaich, M. P., Schutte, A. E., Tomaszewski, M., Touyz, R. M., & Wang, J.-G. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11452 · Cited by 23
Grenet, G., Le, H. H., Bejan-Angoulvant, T., Erpeldinger, S., Boussageon, R., Kassaï, B., Moulin, P., Gueyffier, F., & Cucherat, M. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.05.003 · Cited by 6
Metadata
- Authors
- Brunström, M., & Carlberg, B.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2018-01-01
- Volume
- 178
- Issue
- 1
- Pages
- 28
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W2769574669
- Cited by
- 471
- References
- 117
- FWCI
- 27.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.